This breast cancer thought-leader discussion, with associated slide deck and eNewsflash, provides participants with valuable updates and expert perspectives on exciting new data on the use of PARP inhibitors in breast cancer released at the 2017 Oncology Annual Meeting in Chicago.
Jun 8, 2017
Jun 9, 2018
Abstract LBA4: OlympiAD: Phase III trial of olaparib monotherapy versus chemotherapy for patients (pts) with HER2-negative metastatic breast cancer (mBC) and a germline BRCA mutation (gBRCAm)
Robert Coleman, MD, FRCP, FRCPEMedical Director, prIME Oncology
University of Sheffield
Weston Park Hospital
Sheffield, United Kingdom
Pierfranco Conte, MDIstituto Oncologico Veneto
University of Padua
Andrew Tutt, MD, PhDInstitute of Cancer Research
London, United Kingdom
After successful completion of this educational activity, participants should be able to:
- Identify current and emerging treatment options for patients with HER2-negative metastatic breast cancer
- Describe the impact of BRCA 1/2 testing on clinical outcomes for patients with breast cancer
- Assess recent and ongoing clinical trial data of PARP inhibitors in patients with breast cancer
- Select optimal treatment options for patients with triple-negative and BRCA-mutated breast cancer, based on current treatment guidelines and emerging clinical trial data
This educational activity is supported by a grant from AstraZeneca.
Independent Medical Education (IME)
This IME activity is organized by prIME Oncology. This activity provides content that is evidence-based, balanced, and free of commercial bias, with a primary objective to improve competence and performance of learners in order to improve patient care.
This activity is provided by prIME Oncology.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Disclosure Regarding Unlabeled Use
This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.